Navigation Links
Mandatory Accreditation Delayed Until September 2009
Date:1/10/2008

PMC Commends CMS for Setting Date but Fear that Program Integrity will be Needlessly Compromised in the Interim

WASHINGTON, Jan. 10 /PRNewswire-USNewswire/ -- The Power Mobility Coalition (PMC) today applauded the Centers for Medicare and Medicaid Services (CMS) for setting a date certain when all Medicare DMEPOS suppliers need to be accredited, but expressed concern that it will take close to two years for the requirement to be fully implemented. The PMC, however, further commends CMS for recognizing the need to deploy stronger measures that will better scrutinize suppliers participating in the Medicare program, ensure program integrity and safeguard taxpayer resources.

CMS recently announced that all DMEPOS suppliers need to be accredited by a nationally recognized accreditation body by September 31, 2009 or else their Medicare billing privileges would be revoked. New suppliers must be accredited by January 1, 2009 and suppliers who are applying to participate in the Medicare program after March 1, 2008 must supply proof of accreditation with their application. As part of the Medicare Modernization Act (MMA) of 2003, Congress authorized CMS to establish new quality standards and require accreditation of all Medicare DMEPOS suppliers.

Yet, four years after passage of the MMA and more than a year after development of new quality standards for DMEPOS suppliers, CMS will still allow non-accredited suppliers to serve Medicare beneficiaries for close to another two years. As PMC Director Eric Sokol stated, "For the past year, CMS has had all the tools at their disposal to implement mandatory accreditation. Clearly, DMEPOS suppliers understand the new work load that will be placed on the nationally recognized accreditation bodies. But CMS has been slow in fully implementing the accreditation requirement and extending the deadline to September 2009 is just too long a period of time and will needlessly expose the Medicare program to unscru
'/>"/>

SOURCE The Power Mobility Coalition
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
2. SATELLITE BROADCAST: Consumer Group Says Hillary Clintons Mandatory Health Insurance Plan is an Act of War on the Middle Class that Cant Afford $12k Policy
3. Nunez and Legislators Urged to Oppose Mandatory Purchase of Private Health Insurance
4. Governor Schwarzeneggers Mandatory Purchase of Private Health Insurance Doesnt Add Up for the Middle-Class, Says FTCR
5. Massachusetts Mandatory Health Insurance Purchase Law is No Model for California
6. Governors Health Plan Hides the True Cost of a Mandatory Purchase Requirement, Testimony Shows
7. Nunez Health Reform Bill Establishes Mandatory Purchase Without Linking to Subsidies for Middle Class and Poor
8. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
9. Consumer Group to Nunez: Massachusetts Mandatory Health Insurance Purchase Law Is No Model for California
10. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
11. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 2Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 3Health News:Pill Could Boost Sports Performance 2Health News:Get Straight A's in Snacking with Supercharged Superfruits from Fruitaceuticals! 2Health News:'Who's Who' Weight Specialist Martin Schiff, M.D., 86, Devoting Rest of Life to Spreading Truth About Diets, Won't Accept Compensation From Anyone, Sending Complete Guide Free to All 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 3Health News: Freescale and Monebo Launch ECG-on-a-Chip Platform Solution to Aid Heart Monitoring : Advanced Hardware and Software Technology Designed to Enable More Efficient and Higher Quality Cardiac Care 2
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2
Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 2Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 3Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 4Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 5